Investigational Use of Peptides in Weight Management

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

The exploration of peptides in weight regulation is not entirely novel, but recent years have seen a surge in interest. Traditionally, peptides were applied in medical contexts such as diabetes management, with the primary strategy being the replacement of a missing natural peptide with a synthetic equivalent. Over time, research has expanded beyond this substitution model, showing that peptide derivatives can be engineered to influence distinct metabolic pathways.

When applied to body weight conrol, the objective has been to create compounds that selectively enhance fat utilization while preserving or even augmenting lean tissue. The following review summarizes several of the most studied compounds, highlighting their mechanisms, applications, and current state of research.

Shift Toward Metabolically Targeted Interventions

Earlier approaches to weight loss therapies emphasized broad increases in energy expenditure. While effective in reducing body mass, such strategies often failed to differentiate between fat and lean tissue catabolism. In contrast, peptides provide a more refined method. By engaging with endogenous biochemical processes, these agents can redirect energy use away from adipose storage and toward anabolic processes such as skeletal muscle and bone formation.

Key Compounds Under Investigation

AOD9604 – Growth Hormone Fragment Analogue

AOD9604 is derived from a segment of the human growth hormone (HGH), specifically fragment 176-191. Unlike the parent hormone, which also promotes lean tissue growth, AOD9604 was engineered to retain only the lipolytic (fat-burning) properties. Preclinical and clinical research, particularly from Australia, indicates that this compound accelerates fat loss significantly compared with placebo. Its effects are mediated through beta-3 adrenergic receptors in adipose tissue and may involve induction of programmed fat cell death.

Fragment 176-191 – Isolated HGH Segment

Closely related to AOD9604, this smaller fragment of HGH functions primarily through upregulation of beta-3 adrenergic receptors in adipose cells. Activation of these receptors enhances lipid breakdown. Experimental models suggest a self-regulating effect—promoting fat reduction in obese subjects without causing excessive loss in those of normal weight.

Liraglutide – GLP-1 Receptor Agonist

Liraglutide is a glucagon-like peptide-1 analogue with established clinical use. It enhances insulin release, slows gastric emptying, and decreases gut motility, collectively reducing hunger and caloric intake. Studies also suggest central nervous system activity that suppresses appetite signals. Long-term administration has demonstrated improvements in blood sugar control and reductions in cardiovascular risk factors.

MOTS-c – Mitochondrial-Derived Peptide

MOTS-c is notable for being encoded within mitochondrial DNA rather than the nucleus. This short peptide penetrates cellular, mitochondrial, and nuclear membranes, where it influences multiple metabolic processes. It activates the AMPK pathway, shifting cells toward fat and glucose oxidation, a mechanism also seen in ketogenic dietary states. Additionally, MOTS-c modulates gene expression linked to energy metabolism and antioxidant production, contributing to improved lipid utilization.

5-Amino-1MQ – NNMT Enzyme Inhibitor

Although not technically a peptide, 5-Amino-1MQ is frequently grouped with peptide-based research due to its metabolic effects. It inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that suppresses the futile cycle—a process that dissipates energy as heat. By blocking NNMT, this compound enhances energy expenditure, reduces fat mass, and improves glucose transport into muscle. Animal models demonstrate rapid weight reduction and favorable lipid profile changes.

Semaglutide – GLP-1 Analogue

Semaglutide, another GLP-1 receptor agonist, has been FDA-approved for obesity management. It delays gastric emptying, reduces post-meal glucose surges, and acts centrally to diminish appetite and increase satiety. Clinical trials report substantial and sustained weight reduction, averaging 15% of body mass after one year of therapy.

Tesofensine – Neurotransmitter Reuptake Inhibitor

Tesofensine was initially developed for neurological disorders but demonstrated pronounced weight loss effects. It acts by inhibiting the reuptake of dopamine, serotonin, and norepinephrine, thereby suppressing appetite and reducing caloric intake. Clinical trials have shown significant, dose-dependent reductions in body weight, with some participants losing more than 10% within six months. Researchers consider it a promising candidate for future obesity interventions.

Growth Hormone Secretagogues

Compounds that stimulate endogenous growth hormone release represent one of the earliest classes studied for weight modulation. These agents fall into two groups:

• Growth Hormone Releasing Hormone (GHRH) Analogues – such as sermorelin and CJC-1295, which enhance physiologic GH release. 
• Ghrelin Mimics (GHSR Agonists) – including GHRP-2, GHRP-6, hexarelin, and ipamorelin, which stimulate GH secretion by acting on ghrelin receptors. 

Elevated GH levels support fat mobilization, lean tissue development, improved bone density, and broader metabolic benefits.

Conclusion

Peptides and related compounds represent a major evolution in weight management research. Unlike older interventions that indiscriminately accelerated metabolism, these agents target specific pathways to promote fat loss while safeguarding or enhancing lean tissue. With ongoing clinical trials and increasing FDA approvals, they are positioned to play an important role in the future of obesity treatment.

REFERENCES

1. Axel, A. M., Mikkelsen, J. D., & Hansen, H. H. (2010). Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(7), 1464–1476. https://doi.org/10.1038/npp.2010.16
2. Ryan D. H. (2022). Drugs for Treating Obesity. Handbook of experimental pharmacology, 274, 387–414. https://doi.org/10.1007/164_2021_560
3. Neelakantan, H., Vance, V., Wetzel, M. D., Wang, H. L., McHardy, S. F., Finnerty, C. C., Hommel, J. D., & Watowich, S. J. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical pharmacology, 147, 141–152. https://doi.org/10.1016/j.bcp.2017.11.007
4. Zieba R. (2007). Otyłość: przeglad aktualnie stosowanych leków i nowych zwiazków poddawanych ocenie klinicznej [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Postepy higieny i medycyny doswiadczalnej (Online), 61, 612–626.
5. Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006). Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, obesity & metabolism, 8(4), 436–447. https://doi.org/10.1111/j.1463-1326.2006.00602.x
6. Tang-Christensen, M., Larsen, P. J., Thulesen, J., Rømer, J., & Vrang, N. (2000). The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nature medicine, 6(7), 802–807. https://doi.org/10.1038/77535